摘要
目的:观察吸入噻托溴铵(思力华)联合沙美特罗替卡松(舒利迭)对慢性阻塞性肺疾病(COPD)患者肺功能的影响。方法:随机将40例患者分为舒利迭组(对照组)和噻托溴铵联合舒利迭组(试验组)各20例,所有患者均给予常规抗感染、吸氧、化痰和平喘对症治疗,对照组应用舒利迭,试验组应用思力华联合舒利迭,出院后对照组继续使用舒利迭,试验组继续使用噻托溴铵联合舒利迭,随访观察12周。2组均于治疗前及出院12周查肺功能及进行血气分析。结果:治疗前2组的第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC、FEV1占预计值百分比(FEV1%)、动脉血氧分压[p(O2)]、动脉血二氧化碳分压[p(CO2)]的差异均无统计意义(P>0.05);治疗后试验组较对照组症状明显改善(P<0.05)。结论:舒利迭联合思力华联用对COPD患者肺功能有更显著的改善作用。
Objective：To observe the effects of tiotropium and seretid on pulmonary function in patients with chronic obstructive pulmonary disease （COPD）. Methods：Forty patients with COPD were randomly divided into two groups （n=20 for each group）,seretide （control group） and tiotropium bromide （experimental group）. All patients were treated with routine anti-infection,？oxygen inhalation, relieving phlegm and anti asthma. The patients in experimental group inhaled tiotropium and seretid simultaneously, and patients in control group inhaled seretide. Patients in the two groups continued the treatment discharge. The fellow-up period was 12 weeks. The pulmonary functions were detected before treatment and 12 weeks after discharge in patients of two groups. Results：There were no significant differences in the values of forced expiratory volume in 1 second （FEV1）, forced vital capacity （FVC）, FEV1/FVC,FEV1%,arterial partial pressure of oxygen [p（O2）] and partial pressure of carbon dioxide [p（CO2）] before treatment between two groups （P〈0.05）. But these were significantly improved after treatment in patients of experimental group than those of control group （P〈0.05）. Conclusion：Seretid combined with tiotropium can significantly improve the pulmonary functions in patients with COPD.
出处
《天津医药》
CAS
北大核心
2011年第3期199-201,共3页
Tianjin Medical Journal
关键词
肺疾病
慢性阻塞性
呼吸功能试验
血气分析
投药
吸入
噻托溴铵
沙美特罗替卡松
pulmonary disease
chronic obstructive respiratory function tests blood gas analysis administration
inhalation tiotropium salmeterol and fluticasone propionate（seretide）
